GSK halts clinical development of GSK2251052
GSK discontinued the GSK2251052 trials due to the identification of microbiological findings of resistance in few patients in the Phase 2b trial designed to treat complicated urinary tract
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.